cafepharmaVaccines, next-gen approaches target the toughest cancers: AACR—FDA commissioner tells lawmakers his agency needs more authority to prevent drug shortages—European regulators find no evidence of link between new obesity medicines and suicidal thoughts--http://bit.ly/w28kSd #aacr #oncology #cancer #cancervaccine #fda #drugshortages #ema #novonordisk #obesity #ozempic #wegovy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
🤨 Subterranean Homesick AlienWill not travel to autocratic, theocratic, or democracy-dismantling countries (China, Russia, Iran, North Korea, Afghanistan, Egypt, Israel, the Maldives,…) Also, will not subsidize with my travels any bigoted red state where abortion is illegal and LGBTQ+ persecution is state policy (talking to you #Florida, #Georgia, #Louisiana ). Will pressure medical & research organizations to stop having their yearly conferences in these places #AACR #ASCO #ASH #SITC #Neuroscience Meeting
Douglas Levine, MD 
Great #AACR Special Conference on #EndometrialCancer just posted: https://www.aacr.org/meeting/aacr-special-conference-endometrial-cancer/
AACR Special Conference: Endometrial Cancer
November 16-18, 2023Sheraton Boston HotelBoston, Massachusetts Conference Cochairs Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, North CarolinaDeborah F. DeLair, Northwell Health, Greenvale, New YorkDouglas A. Levine, Merck Research Laboratories, Rahway, New Jersey
Alex SilverConcise & timely review from my colleague Sarah Reed out in #AACR #ClinicalCancerResearch about #ClonalHematopoiesis in #SolidTumors. See the nice summary figure below and find the full text here: https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-22-2598/711363/CHIP-Happens-Clonal-hematopoiesis-of-indeterminate #medicine #science #hematology #oncology #cancer #immunology
CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors
Abstract. Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates to these known outcomes, much remains to be learned about the development and role of CHIP in other disease states. Emerging research has identified high rates of CHIP in patients with solid tumors, driven in part by oncologic therapy, and revealed associations between CHIP and differential outcomes in both solid tumors and other diseases. Recent studies have demonstrated that CHIP can contribute to dysregulated inflammatory signaling in multiple contexts, underscoring the importance of interrogating how CHIP might alter tumor immunology. Here, we review the role of CHIP mutations in clonal expansion of hematopoietic cells, explore the relationship between CHIP and solid tumors, and discuss the potential roles of CHIP in inflammation and solid tumor biology.
Josh GoldsteinBrain cancer survivor and #AACR #Runners4Research team member ran Philly to save lives and finished in an impressive 2 hours and 48 minutes. Congratulations to Aaron and all the runners at this year’s #AACR #PhiladelphiaMarathon which raised over $525,000 for #cancerresearch! Aaron (right) with his fiancé, parents, and brother after the race.
An American Association for Cancer Research #Runners4Research team member runs by historic Independence Mall during the #AACR #PhillyMarathon. Thanks to all the Runners for Research who have raised over $525,000 for lifesaving #cancerresearch so far. There’s still time to support them, donate at https://bit.ly/3GwjeJm
Excited for the American Association for Cancer Research #PhiladelphiaMarathon kicking off in a few minutes. Thank you to the #AACR #Runners4Research who have raised over $500,000 for lifesaving cancer research.
